Apellon Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 05-01-2025
- Paid Up Capital ₹ 0.12 M
as on 05-01-2025
- Company Age 11 Year, 16 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.57 M
as on 05-01-2025
- Satisfied Charges ₹ 1.50 M
as on 05-01-2025
- Revenue 4.36%
(FY 2021)
- Profit 18.38%
(FY 2021)
- Ebitda 26.07%
(FY 2021)
- Net Worth 41.79%
(FY 2021)
- Total Assets 33.14%
(FY 2021)
About Apellon Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.12 M.
The company currently has active open charges totaling ₹6.57 M. The company has closed loans amounting to ₹1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Nikita Marwaha, Dinesh Kumar, and Indu Gupta serve as directors at the Company.
- CIN/LLPIN
U24232PB2014PTC038266
- Company No.
038266
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jan 2014
- Date of AGM
30 Nov 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Amritsar, Punjab, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Apellon Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nikita Marwaha  | Director | 08-Jan-2014 | Current |
| Dinesh Kumar | Director | 08-Jan-2014 | Current |
| Indu Gupta | Director | 08-Jan-2014 | Current |
Financial Performance of Apellon Biotech.
Apellon Biotech Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 4.36% increase. The company also saw a substantial improvement in profitability, with a 18.38% increase in profit. The company's net worth Soared by an impressive increase of 41.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apellon Biotech?
In 2021, Apellon Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹6.57 M
₹1.50 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.66 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Apr 2023 | Hdfc Bank Limited | ₹1.57 M | Open |
| 10 May 2016 | Hdfc Bank Limited | ₹5.00 M | Open |
| 08 Jan 2015 | State Bank Of India | ₹1.50 M | Satisfied |
How Many Employees Work at Apellon Biotech?
Unlock and access historical data on people associated with Apellon Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apellon Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apellon Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.